tbuckley/cabot-search huggingface dataset:
GENE-34. THERAPEUTICALLY TARGETING EPIGENOMIC AND TRANSCRIPTIONAL DYSFUNCTION IN ATRX-DEFICIENT GLIOMA
Authors: Carla Danussi, Anand Singh, Pavan Pinnamaneni, Grant Fisher, David Picketts, Kasthuri Kannan, Arvind Rao, Kunal Rai, Jason Huse
Journal: Neuro-Oncology (2019)

Abstract Diffusely infiltrating gliomas feature loss-of-function mutations in the chromatin remodeler gene ATRX as defining molecular alterations delineating major adult and pediatric disease subtypes. We recently reported that Atrx deficiency drives glioma-relevant phenotypes, such as increased motility and astrocytic differentiation profiles, by directly modulating epigenomic landscapes and the corresponding transcriptional profiles in glioma cells of origin. In particular, Atrx deficiency was associated with disruptions in H3.3 histone content at key genetic loci. To further understand the downstream epigenomic dysfunction induced by ATRX deficiency, we compared genome-wide chromatin-state maps of Atrx+ and Atrx- primary murine neuroepithelial progenitors (mNPCs). This ChIP–seq analysis revealed major differences in the localization of heterochromatin repressive marks H3K9me3 and H3K27me3. Specifically, we identified peculiar locations in the genome displaying H3K9me3 depletion and gain of H3K27me3 upon Atrx inactivation. Interestingly, these regions were flanked by Atrx binding sites and perfectly co-localized with Lamina-Associated Domains, known to play important roles in tissue lineage specification. To better target this dysfunction, we utilized the Broad Institute Connectivity Map (CLUE analysis) to identify compounds likely to revert the unique transcriptional perturbations induced by Atrx deficiency. We found that HDAC inhibitors, as a compound class, yielded expression profiles strongly anticorrelated to those driven by Atrx deficiency in these datasets. Further integrating existing gene expression data from our mNPCs and the TCGA LGG project with our CLUE findings highlighted SIRT2, a class III HDAC, as a top potential target. SIRT2 expression was significantly upregulated in both Atrx- mNPCs and in ATRX-mutant gliomas and its specific chemical inhibition normalized cellular motility in both Atrx- mNPCs and ATRX-mutant, patient derived glioma stem cells. These findings indicate that SIRT2 inhibition represents a viable strategy to revert the epigenetic effects of ATRX deficiency on facultative heterochromatin and their transcriptional and phenotypic consequences.
Torsion of the Gall-bladder
Authors: E. W. O. Skinner
Journal: BMJ (1953)

Studies of structure-transacylation relationships for a series of acylhydroxamic acids of chlorinated biphenyl ethers and their related compounds by rat liver N-arylacylhydroxamic acid-dependent N-acyltransferase (AHNAT) are described. In the transacylation of 4-aminoazobenzene catalyzed by AHNAT, 4-substituents (chloro, phenoxy, and mono-, di-, and trichlorophenoxy groups) of N-phenylacetohydroxamic acid enhanced the ability of the unsubstituted hydroxamic acid to serve as acetyl donors. As to the number of chlorines in the phenoxy group, the activity increased with decreasing number from three to zero. Of the monochlorophenoxy compounds, the 49-chloro compound was the most effective acetyl donor. In 3-substituents (chloro and phenoxy groups) of N-phenylacetohydroxamic acid, the 3-chloro compound was an effective acetyl donor similarly to the 4-chloro compound, whereas the 3-phenoxy compound was 48% as active as the 4-phenoxy compound. None of 2-substituted N-phenylacetohydroxamic acids examined showed transacetylation activity. As to the effect of acyl group structure on the activity, N-propionyl, N-glycoloyl, and N-formyl derivatives of the 4-(49-chlorophenoxy) compound were only 4, 2, and 0% as active as the corresponding acetyl compound, respectively. Esterification of the N-arylacetohydroxamic acid decreased the activity; O-acetyl, O-methyl, O-glucosyl, and O-glucuronosyl derivatives of the 4-(49-chlorophenoxy) compound were 35, 7, 0, and 0% as active as the corresponding N-hydroxy compound, respectively.
To Control Costs Expand Managed Care and Managed Competition
Authors: Alain Enthoven, Victor R. Fuchs, Stephen M. Shortell
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ATIM-18. SURVIVAL OF SUBJECTS WITH RECURRENT GLIOBLASTOMA RECEIVING INTRA-TUMORAL ADMINISTRATION OF IL-12 MANAGED WITH LOW-DOSE DEXAMETHASONE
Authors: Rimas Lukas, Ennio Chiocca, Sylvia Kurz, John Yu, Joseph Landolfi, Ganesh Rao, Jill Buck, Nathan Demars, Amy Smith, John Miao, John Zhou, Yunxia Wang, Arnold Gelb, Laurence Cooper
Journal: Neuro-Oncology (2019)

Abstract Ad-RTS-hIL-12 (Ad) is a novel gene therapy, conditionally expressing IL-12 via the RheoSwitch Therapeutic System® (RTS®) gene switch under control of an oral activator ligand, veledimex (V). We previously reported results from 51 subjects (NCT02026271 and NCT03679754) describing biological activity of controlled IL-12, safety and survival data. Previously, subjects who received Ad+V (20 mg) managed with low-dose dexamethasone in the Main study achieved a mOS of 17.8 months, which is approximately twice the anticipated survival compared to historical controls. The mechanism of action of Ad+V is based on controlled secretion of recombinant IL-12 (measured in peripheral blood as a surrogate for intra-tumor-production), downstream upregulation of endogenous IFN-g (measured in peripheral blood), and an increase in the “cytoindex” (ratio of circulating CD8+ T cells to FoxP3+ regulatory T cells), an emerging biomarker of overall survival. Herein we provide an update of subject characteristics, survival and biomarker analysis from the ongoing Phase 1 and expansion substudy. assessing safety and tolerability of local, inducible IL-12 by single intratumoral injection of Ad (2 x 1011 viral particles) + V (20 mg PO QD x15 doses Days 0–14) in subjects, including a subset receiving low-dose corticosteroids (≤20 mg cumulative dexamethasone Days 0–14). Drug-related toxicities were predictable, dose-related, and promptly reversible upon discontinuation of V with no drug-related deaths. Biomarker studies related to production of IL-12 and IFN-g, as well as cytoindex remain encouraging. As of 04Jun19, mOS in the Expansion substudy had not yet been reached (patient enrollment occurred from September 2018-February 2019). Most subjects (65%) received low-dose dexamethasone (cumulative ≤20mg Days 0–14); initial impact of this and other subject characteristics on survival will be presented.
Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma
Authors: Genevive Hernandez, Ling-Yuh Huw, Anton Belousov, Deanna Wilson, Hartmut Koeppen, Ron McCord, Kun Peng, Nancy L Bartlett, Lihua E Budde, Sarit Assouline, Loretta J. Nastoupil, Dok Hyun Yoon, Matthew J Matasar, Brendan Bender, Antonia Kwan, Chi-Chung Li, Carol O'Hear, Shen Yin, Michael C Wei, Joanne I Adamkewicz
Journal: Blood (2019)
Durable Responses and Survival in High Risk AML and MDS Patients Treated with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine
Authors: Luca L.G. Janssen, Theresia M. Westers, Jeroen Rovers, Peter Valk, Jacqueline Cloos, Tanja D. de Gruijl, Arjan A. Van de Loosdrecht
Journal: Blood (2019)
Procoagulant Microparticles Derived from Myeloma Plasma Cells Have a Determinant Role in the Hypercoagulable State Associated with Multiple Myeloma. a Modelization in Vitro Study
Authors: Loula Papageorgiou, Patrick Van Dreden, Meletios A. Dimopoulos, Annette Larsen, Mohamad Mohty, Ismail Elalamy, Grigorios T. Gerotziafas
Journal: Blood (2019)
DRES-09. REGULATORY EFFECTS OF THE CILIARY GTPASE ARL13B ON PURINE METABOLISM IN GBM
Authors: Miranda Saathoff, Jack Shireman, Eunus Ali, Cheol Park, Issam Ben-Sahra, Atique Ahmed
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma (GBM) is the most common form of adult primary brain cancer. Despite an aggressive treatment regimen – surgical resection, irradiation, and temozolomide (TMZ) chemotherapy – patients’ prognosis is still grim. TMZ acts by methylating purines, specifically at the O6 and N7 positions of guanine, to induce cytotoxic DNA double-strand breaks. We thus wanted to explore how purine metabolism may contribute to TMZ-resistance. In mammalian cells, purine nucleotides can be recycled by the salvage pathway or generated via de novo synthesis. The salvage pathway is energetically inexpensive relative to de novo thus, highly proliferative GBM cells preferentially utilize the salvage pathway. We have shown that salvage synthesis is reduced in response to TMZ (p-value=0.0021), hinting that the cells may utilize de novo to evade therapy induced alkylation of purines. Using immunoprecipitation-mass spectroscopy analysis, we found a novel interaction between the ciliary GTPase ARL13B and IMPDH2, the rate-limiting enzyme in de novo synthesis. We have shown that this interaction, occurring at the C-terminal domain of ARL13B, plays a significant role in the regulation of purine biosynthesis as abolishing it through ARL13B knockdown reduced flux through de novo (p-value&lt; 0.0001) synthesis as measured by the specific activity of IMPDH2. Further, the lentiviral-mediated rescue of ARL13B brings IMPDH2 activity back to basal levels (p&lt; 0.0001). Given its canonical function as a GTPase, we hypothesize that ARL13B acts as a novel regulator of de novo synthesis by sequestering GDP, allowing IMPDH2 to sense and respond to the cytosolic levels of guanine nucleotides. Without ARL13B the de novo pathway is halted, forcing the cells to rely on salvage to replenish nucleotide pools. Reliance on this pathway in the presence of TMZ causes cells to incorporate damaged nucleotides as a result of the drug’s alkylating action leading to the increased therapeutic efficacy of TMZ.
Annals Story Slam - Along Came Molly
Authors: Nicola Goldberg
Journal: Annals of Internal Medicine (2019)

Web Exclusives5 November 2019Annals Story Slam - Along Came MollyFREENicola Goldberg, MDNicola Goldberg, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W19-0029 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Along Came Molly "Along Came Molly," by Nicola Goldberg, MD (Duration 4:25)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 5 November 2019Volume 171, Issue 9Page: SS1 ePublished: 5 November 2019 Issue Published: 5 November 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.Loading ...
Acute Dilatation of the Stomach
Authors: M. Lee, E. Somerville
Journal: BMJ (1941)

a definite odour of putrefaction.For longer periods it is possible that larger amounts of sugar may be needed.These could be provided by increasing the concentration of the solution or by adding crystalline lactose to the dressings.With the use of lactose both the amount of exudate and the tendency to excoriation of the surrounding skin appear to be diminished, probably because bac- terial production of proteolytic enzymes is decreased in the presence of utilizable carbohydrate (Kendall, 1923).The usual healing process does not seem to be impaired by the addition of sugar.The dressings do not become adherent to the wound as is sometimes the case -with vaselined gauze.Since B. pyocyaneuis has little or no ability to utilize sugar this method does not affect its odour, which, however, is not nearly so offensive and penietratinig as that of true putrefaction.It is to be hoped that the use of lactose will prove as satisfactory in compound fractures as it has in osteo- myelitis.
Prognostic Molecular Stratification in Relapsed/Refractory Multiple Myeloma - Results of the Pomalidomide Mukseven (NCT02406222) Biomarker Trial
Authors: James Croft, Andrew Hall, Amy L Sherborne, Katrina Walker, Sidra Ellis, Kim Sharp, Amy Price, Charlotte Pawlyn, Louise Flanagan, Mamta Garg, Suzana Couto, Maria Wang, Kevin Boyd, William E Pierceall, Anjan Thakurta, Gordon Cook, Sarah R Brown, Martin F. Kaiser
Journal: Blood (2019)
The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI)
Authors: Koji Sasaki, Josep-Maria Ribera, Mary Figueroa, Farhad Ravandi, Nicholas J. Short, Guillermo Garcia-Manero, Naval G. Daver, Tapan M. Kadia, Marina Y Konopleva, Nitin Jain, Ghayas C. Issa, Zeev E. Estrov, Rebecca Garris, Rita Khouri, Patrice Nasnas, Courtney D. DiNardo, Kiran Naqvi, Steven M. Kornblau, Guillermo Montalban-Bravo, Naveen Pemmaraju, Jorge E. Cortes, Susan M. O'Brien, Joya Chandra, Hagop M. Kantarjian, Elias Jabbour
Journal: Blood (2019)
Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms
Authors: Kelly L. Schoenbeck, Giselle Salmasi, Miguel Carlos Cerejo, Patricia A. Cornett, Lloyd E. Damon, Aaron C. Logan, Rebecca L. Olin, Andrew D. Leavitt, Catherine C. Smith
Journal: Blood (2019)
Bioengineered miR-328-3p modulates GLUT1-mediated glucose uptake and metabolism to exert synergistic antiproliferative effects with chemotherapeutics
Authors: Wanrong Yi, Mei-Juan Tu, Zhenzhen Liu, Chao Zhang, Neelu Batra, Ai-Xi Yu, Ai-Ming Yu
Journal: Acta Pharmaceutica Sinica B (2019)

MicroRNAs (miRNAs or miRs) are small noncoding RNAs derived from genome to control target gene expression. Recently we have developed a novel platform permitting high-yield production of bioengineered miRNA agents (BERA). This study is to produce and utilize novel fully-humanized BERA/miR-328-3p molecule (hBERA/miR-328) to delineate the role of miR-328-3p in controlling nutrient uptake essential for cell metabolism. We first demonstrated successful high-level expression of hBERA/miR-328 in bacteria and purification to high degree of homogeneity (>98%). Biologic miR-328-3p prodrug was selectively processed to miR-328-3p to suppress the growth of highly-proliferative human osteosarcoma (OS) cells. Besides glucose transporter protein type 1, gene symbol solute carrier family 2 member 1 (GLUT1/
Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data
Authors: Yafit Segman, Elena Ribakovsky, Abraham Avigdor, Vladimir Vainstein, Neta Goldschmidt, Shimrit Ringelstein Harlev, Odit Gutwein, Uri Abadi, Anatoly Nemets, Orit Sofer, Najib Dally, Kalman Filanovsky, Merav Leiba, Nadav Sarid, Noam Benyamini, Yair Herishanu, Ron Ram, Chava Perry, Irit Avivi
Journal: Blood (2019)
A Randomized Phase 3 Clinical Trial of the Combination of Plinabulin (plin) + Pegfilgrastim (peg) Versus (vs) Peg Alone for Tac (docetaxel, doxorubicin, cyclophosphamide) Induced Neutropenia (cin)
Authors: Douglas W. Blayney, Lan Huang, Ramon Mohanlal
Journal: Blood (2019)
Levetiracetam is a useful alternative to phenytoin for epileptic seizures in children
Authors: Rob Cook, Peter Davidson, Rosie Martin
Journal: BMJ (2019)

The study Lyttle MD, Rainford NEA, Gamble C, et al. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Lancet 2019;393:2125-34. This trial was funded by the NIHR Health Technology Assessment Programme (project number 12/127/134). To read the full NIHR Signal, go to https://discover.dc.nihr.ac.uk/content/signal-000790/levetiracetam-vs-phenytoin-in-stopping-childrens-prolonged-epileptic-seizures
INNV-29. PHOTODYNAMIC THERAPY FOR MALIGNANT BRAIN TUMORS
Authors: Kazuhiro Tanaka, Takashi Sasayama, Tomoaki Nakai, Eiji Kohmura
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Photodynamic therapy (PDT) uses the toxicity of singlet oxygen generated by a reaction between a photosensitizer in tumor cells and light with a specific wavelength. Recently, PDT for primary malignant brain tumors was approved in Japan. We retrospectively analyzed the patients treated with PDT in our hospital. METHODS From August 2017 to February 2019, total 16 patients were performed PDT in our hospital. After the tumor had been resected as extensively as possible, the region of probable tumor invasion in the resection cavity were irradiated superficially with a 664-nm diode laser for 180 sec (27 J/cm2) at a power density of 150 mW/cm. The characteristics of patients, the number of irradiation, adverse events, changes of the MR image, and clinical outcome were analyzed. RESULTS In histological examination, glioblastoma (GBM) were eleven cases, anaplastic oligodendroglioma were two cases, and other three cases were anaplastic astrocytoma, malignant meningioma, and malignant lymphoma. The mean tumor volume was 46.1 ml. Gross total resection, Subtotal resection, and partial resection were performed in 11 patients, 3 patents, and 2 patients, respectively. The mean number of laser irradiated sites was 15 (5~31 sites). Radiologically, the irradiated region indicated high intensity in diffusion-weighted image, which gradually disappeared for 2 weeks without neurological deterioration. In adverse events, venous congestion and brain swelling were observed in one patient. Three GBM patients were dead with tumor recurrence during a mean follow-up period of 24.4 months. CONCLUSION PDT was safe and useful for malignant brain tumors. However, PDT-induced specific changes in the tumor tissue should be monitored carefully.
Comparison of the Serum Metabolic Signatures Based on 1 H NMR between Thrombotic Antiphospholipid Syndrome (APS) Patients and Healthy Individuals
Authors: Melissa Quintero, Silmara Aparecida De Lima Montalvão, Ljubica Tasic, Stephany Cares Huber, Joyce Maria Annichino- Bizzacchi
Journal: Blood (2019)
The Geriatric Syndrome of Sarcopenia Impacts Allogeneic Hematopoietic Cell Transplantation Outcomes in Combination with Multi-Morbidity and Functional Impairment
Authors: Richard J Lin, Laure Michaud, Stephanie M Lobaugh, Reiko Nakajima, Theresa A Elko, Josel D Ruiz, Craig S. Sauter, Parastoo B. Dahi, Molly A. Maloy, Miguel-Angel Perales, Soo Jung Kim, Beatriz Korc-Grodzicki, Sean M. Devlin, Michael Scordo, Heiko Schoder, Sergio A Giralt, Paul A. Hamlin
Journal: Blood (2019)
KLF6 INTERACTS WITH FXR TARGET GENES AND EFFECTS THE OUTCOME OF PRIMARY SCLEROSING CHOLANGITIS
Authors: Svenja Sydor, Paul Manka, Lea Van Buren, Janette Heegsma, Jan Best, Hideo Baba, Guido Gerken, Han Moshage, Scott L. Friedman, Klaas Nico Faber, Ali E. Canbay, Lars Peter Bechmann
Journal: Hepatology (2019)
PULMONARY HYPERTROPHIC OSTEOARTHROPATHY.
Authors: N. S. DAVIS
Journal: JAMA (1895)

I have chosen this symptom group for description as it is one that has received little attention from American writers. It has been my fortune to find but one case described in the literature of this country. This was written by Dr. Packard<sup>1</sup>and published in the<i>American Journal of Medical Sciences</i>for June, 1892. In European literature I find more than forty cases described during the last five years. The characteristic lesions were first pointed out by Marie<sup>2</sup>in 1890 and received from him their name. His attention was attracted to these cases by the need of differentiating them clearly from acromegalia, which he described first in 1886. He found that many observers confounded these disorders which in some respects resemble one another. Moreover he believed that the bone lesions of pulmonary hypertrophic osteo-arthropathy were always due to the absorption of a chemical irritant produced by a
Screening for Pineal Trilateral Retinoblastoma Revisited
Authors: Marcus C. de Jong, Wijnanda A. Kors, Annette C. Moll, Pim de Graaf, Jonas A. Castelijns, Robin W. Jansen, Brenda Gallie, Sameh E. Soliman, Furqan Shaikh, Helen Dimaras, Tero T. Kivelä
Journal: Ophthalmology (2019)
The aryl hydrocarbon receptor (AhR) as a breast cancer drug target
Authors: Jennifer R. Baker, Jennette A. Sakoff, Adam McCluskey
Journal: Medicinal Research Reviews (2019)

Abstract Breast cancer is the most common cancer in women, with more than 1.7 million diagnoses worldwide per annum. Metastatic breast cancer remains incurable, and the presence of triple‐negative phenotypes makes targeted treatment impossible. The aryl hydrocarbon receptor (AhR), most commonly associated with the metabolism of xenobiotic ligands, has emerged as a promising biological target for the treatment of this deadly disease. Ligands for the AhR can be classed as exogenous or endogenous and may have agonistic or antagonistic activity. It has been well reported that agonistic ligands may have potent and selective growth inhibition activity in a number of oncogenic cell lines, and one (aminoflavone) has progressed to phase I clinical trials for breast cancer sufferers. In this study, we examine the current state of the literature in this area and elucidate the promising advances that are being made in hijacking the cytosolic‐to‐nuclear pathway of the AhR for the possible future treatment of breast cancer.
An International Multicenter Study of Intravenous Bevacizumab for the Treatment of Chronic Bleeding and Anemia in Hereditary Hemorrhagic Telangiectasia: The Inhibit-Bleed Study
Authors: Hanny Al-Samkari, Raj S. Kasthuri, Hasan A. Albitar, Yahya Almodallal, Marcelo M. Serra, Carolina Vazquez, Sophie Dupuis-Girod, Clifford R. Weiss, Muhammad A. Latif, Mary Elizabeth Meek, David J. Kuter, Vivek N. Iyer
Journal: Blood (2019)
Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses
Authors: Colleen Annesley, Corinne Summers, Michael A. Pulsipher, Alan S. Wayne, Julie Rivers, Adam J. Lamble, Ashley Wilson, Qian Vicky Wu, Adam Brand, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, Michael C. Jensen, Rebecca Gardner
Journal: Blood (2019)